ToleRx

Parents

2011: Experimental drug for Type 1 diabetes failed to meet the main clinical goal of a late-stage study, called Defend-1 (2011)
Cambridge, Massachusetts
Founded 2008
Immunology
In October 2007, the company and Glaxo formed an alliance that could be worth as much as $760 million to develop otelixizumab for Type 1 diabetes and other diseases
It has raised cash from HealthCare Ventures, Skyline Ventures, and Sprout Group, and secured support from the Juvenile Diabetes Research Foundation.
Tolerx co-founder and CEO Doug Ringler.
Tolerx, After a Decade and $150M, Eagerly Awaits Data from Big Diabetes Trial (2010)
Tolerx’s idea is that it can create drugs that could treat autoimmune diseases by training the immune system to “tolerate” the healthy tissues that it attacks in such ailments, which include Type 1 diabetes, rheumatoid arthritis, and psoriasis